Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda To Purchase IDM Pharma To Boost Oncology Business

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical May 18 announced a buyout plan to acquire U.S. biopharmaceutical company IDM Pharma. Takeda plans to pay $75 million to obtain all outstanding shares of the Nasdaq-listed company. IDM has obtained approval in the EU for Mepact (mifamurtide), the first treatment approved for osteosarcoma. Through the buyout, Takeda plans to market the drug through marketing branches in Europe and expand its oncology business in the European market. (Click here for more - Japanese language

You may also be interested in...



P&G Given Green Light To Offload Haliborange Supplements

P&G's decision to offload its Haliborange children's supplement line will not lead to reduced competition in the UK market, according to the regulator.

Fresenius Kabi Partners On Propofol Supply For COVID-19

Fresenius Kabi’s Diprivan sedative was added to the US FDA’s drug shortage list in April as the COVID-19 pandemic peaked. A long-term committed purchasing agreement signed between the German firm and Premier Inc. will guarantee adequate supply and manage any future surges, the US hospitals group believes.

CanSino Moving Coronavirus Vaccine To Phase III

CanSino plans to start a Phase III study soon for its candidate with a 40,000 enrollment target, discloses its co-founder.

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel